2. Search Result
Search Result
Results for "

Salmonella enterica

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

5

Biochemical Assay Reagents

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-17390A
    Loxapine succinate
    1 Publications Verification

    		 5-HT Receptor Dopamine Receptor Infection Neurological Disease
    Loxapine succinate is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppresses bacterial efflux pump activity and inhibit intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages .
    Loxapine succinate
  • HY-D1056C5
    Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant)

    LPS, from Salmonella enterica (Serotype minnesota Re 595 (Re mutant))

    		 Toll-like Receptor (TLR) Bacterial Inflammation/Immunology
    Lipopolysaccharides (LPS), from S. enterica (Salmonella enterica) serotype minnesota Re 595 (Re mutant) is prepared from Salmonella enterica strain Re 595 (Re mutant). The structure in the LPS of strain Re 595 was shown to induce secretion and aggregation in human platelets .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant)
  • HY-N7389A
    GDP-D-mannose disodium

    		Endogenous Metabolite Drug Intermediate Metabolic Disease
    GDP-D-mannose disodium consists of GDP-α-D-mannose (HY-N7389B) and GDP-β-D-mannose. GDP-α-D-mannose serves as a donor substrate for mannosyltransferases and acts as a precursor of GDP-β-L-fucose. GDP-α-D-mannose exerts competitive inhibition on GTP (with a Ki value of 14.7 μM) and non-competitive inhibition on mannose-1-P (with a Ki value of 115 μM). GDP-D-mannose disodium is metabolized to GDP-L-fucose (HY-134433) via GMDS (Gmd) and TSTA3 (WcaG) .
    GDP-D-mannose disodium
  • HY-W423191
    Maltobionic acid

    4-O-α-D-Glucopyranosyl-D-gluconic acid

    		 Nuclear Factor of activated T Cells (NFAT) Bacterial Infection Metabolic Disease
    Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H2O2)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .
    Maltobionic acid
  • HY-D1056C3
    Lipopolysaccharides, from S. enterica serotype typhimurium

    LPS, from Salmonella enterica (Serotype typhimurium)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype typhimurium are lipopolysaccharide endotoxins and TLR4 activators derived from serotype typhimurium of Salmonella enterica, and are classified as S-type LPS. Lipopolysaccharides, from S. enterica exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype typhimurium can modulate the fate of bacteria in dendritic cells (DC), determining the uptake, degradation, and activation of immune functions by DC cells against the bacteria .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype typhimurium
  • HY-D1056C1
    Lipopolysaccharides, from S. enterica serotype enteritidis

    LPS, from Salmonella enterica (Serotype enteritidis)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype enteritidis
  • HY-155230
    T3SS-IN-2

    		Bacterial Infection
    T3SS-IN-2 (Compound 2h) is a type three secretion system (T3SS) inhibitor. T3SS-IN-2 can be used for bacterial infection research .
    T3SS-IN-2
  • HY-17390AR
    Loxapine succinate (Standard)

    		Reference Standards 5-HT Receptor Dopamine Receptor Infection Neurological Disease
    Loxapine (succinate) (Standard) is the analytical standard of Loxapine (succinate). This product is intended for research and analytical applications. Loxapine succinate is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppresses bacterial efflux pump activity and inhibit intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages .
    Loxapine succinate (Standard)
  • HY-D0200
    Adipic acid dihydrazide

    Adipodihydrazide

    		 Bacterial Drug Intermediate Biochemical Assay Reagents Infection
    Adipic acid dihydrazide (Adipodihydrazide) is an antibacterial agent and crosslinking agent. Adipic acid dihydrazide can be used for the preparation of hydrogels. Adipic acid dihydrazide exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria, such as Enterobacter aerogenes (MIC: 0.081 mg/mL) and Salmonella enterica (MIC: 0.99 mg/mL). Adipic acid dihydrazide is also an important intermediate that can be utilized in the synthesis of other active compounds .
    Adipic acid dihydrazide
  • HY-D1056C4
    Lipopolysaccharides, from S. enterica serotype abortus equi

    LPS, from Salmonella enterica (Serotype abortus equi)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype Abortusequi are lipopolysaccharide endotoxins and TLR-4 activators derived from the Abortusequi serotype of S. enterica, classified as a mutated R-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype abortus equi consist of core oligosaccharide (core oligosaccharide) and lipid A (Lipid A). S. enterica serotype Abortusequi is a major pathogen causing abortion in mares and is also associated with neonatal sepsis, multiple abscesses, orchitis, and polyarthritis in equids. It is primarily grouped based on lipopolysaccharides (O-antigen) and flagellin (H-antigen) .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype abortus equi
  • HY-W040271
    N-3-Hydroxydecanoyl-DL-homoserine lactone

    		Bacterial Antibiotic Infection
    N-3-Hydroxydecanoyl-DL-Homoserine lactone is a bacterial quorum-sensing molecule. N-3-Hydroxydecanoyl-DL-Homoserine lactone activates the transcription factor SdiA (EC50 = 0.6 µM), which detects N-acyl homoserine lactones (AHLs), and exerts its effect in Salmonella enterica (S. enterica) 1 2.
    N-3-Hydroxydecanoyl-DL-homoserine lactone
  • HY-158425
    Antimicrobial agent-31

    		Bacterial Infection
    Antimicrobial agent-31 (compound 4a) is a potent antimicrobial agent. Antimicrobial agent-31 inhibits Salmonella enterica serovar Typhimurium and E.coli with MIC values of 19.24, 11.31 µg/mL, respectively .
    Antimicrobial agent-31
  • HY-130718
    ThrRS-IN-1

    		Bacterial Infection Cancer
    ThrRS-IN-1 (Compound 30d) is a threonyl-tRNA synthetase (ThrRS) inhibitor with an IC50 of 1.4 µM and a Kd of 1.36 µM against Salmonella enterica ThrRS (SeThrRS). ThrRS-IN-1 simultaneously targets the tRNA Thr and L-threonine binding pockets of ThrRS. ThrRS-IN-1 shows potent antibacterial activities .
    ThrRS-IN-1
  • HY-146263
    ThrRS-IN-3

    		Bacterial Infection
    ThrRS-IN-3 (compound 36j) is a highly potent threonyl-tRNA synthetase (ThrRS) inhibitor, with an IC50 value of 19 nM and a Kd of 34 nM for Salmonella enterica ThrRS. ThrRS-IN-3 has antibacterial activities .
    ThrRS-IN-3
  • HY-141467S
    Propionyl CoA-d5

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Propionyl CoA-d5 is the deuterium labeled Propionyl CoA (HY-141467). Propionyl CoA serves as a common intermediate in the catabolic pathways of 1,2-propanediol and propionate in Salmonella enterica serovar Typhimurium LT2, and also functions as a precursor for 2-methylcitrate. Propionyl CoA is utilized as a substrate for the 2-methylcitrate synthase (PrpC) enzyme to synthesize 2-methylcitrate .
    Propionyl CoA-d5
  • HY-151458
    VEGFR-2/DHFR-IN-1

    		VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal Infection Cancer
    VEGFR-2/DHFR-IN-1 (compound 8b) is an inhibitor of VEGFR-2 and DHFR with IC50s of 0.384 and 7.881 μM, respectively. VEGFR-2/DHFR-IN-1 shows good antibacterial activities against Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA and MRSA with MIC values of 16, 16, 16, 8, and 16 μg/mL, respectively. VEGFR-2/DHFR-IN-1 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC50 values of 2.97-7.12 μM. VEGFR-2/DHFR-IN-1 can be used for the research of cancer .
    VEGFR-2/DHFR-IN-1
  • HY-N18102
    3,4-Seco-mansumbinoic acid

    		Bacterial Infection
    3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
    3,4-Seco-mansumbinoic acid
  • HY-182305
    VKT-17-P4-23

    		Bacterial Infection
    VKT-17-P4-23 is a blood-brain barrier-permeable DksA inhibitor. DksA is a highly conserved transcriptional regulator in Gram-negative bacteria, with a Kd of 124 μM. Through the DksA-regulated, SPI-2-dependent survival pathway, VKT-17-P4-23 exhibits antibacterial activity against both planktonic and intracellular pathogens such as Salmonella, and also effectively combats persistent bacteria that are difficult to eliminate. VKT-17-P4-23 can be used in studies of Salmonella infection .
    VKT-17-P4-23
  • HY-181751
    FabI-IN-1

    		Bacterial Infection
    FabI-IN-1 is a FabI (enoyl-acyl carrier protein reductase) inhibitor with a Ki of 0.32 μM against E. coli FabI. FabI-IN-1 inhibits exhibits activity against Gram-negative bacteria including Escherichia coli (MIC = 6.25 μM) and Klebsiella pneumoniae. FabI-IN-1 rescues Galleria mellonella larvae from lethal Escherichia coli infection. FabI-IN-1 exerts a synergistic effect with Colistin (HY-113678) against Escherichia coli. FabI-IN-1 can be used for the research of gram-negative bacterial infection .
    FabI-IN-1

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: